When was Neuronex founded?

Neuronex was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Neuronex located?

Neuronex is headquartered in Morrisville, United States.

How many employees does Neuronex have?

As of May 31, 2026, the latest employee count at Neuronex is 5.

Is Neuronex a funded company?

Neuronex is a funded company, having raised a total of $1.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 07, 2010.

When was the latest funding round of Neuronex?

Neuronex's latest funding was a $***** Conventional Debt round on May 06, 2011, with participation from 0 investor.

Where does Neuronex rank among its competitors?

Neuronex ranks 432nd amongst 492 active competitors, of which 164 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $372M in Jul, 2025.

Who are the top competitors of Neuronex?

Neuronex's top competitors include Jazz Pharmaceuticals, Pacira and Intra-Cellular Therapies. Among them, MapLight secured the most recent funding round in July, 2025.

Neuronex - 2026 Company Profile, Funding & Competitors

Company Details

Neuronex is a development stage company focused on drugs that treat Central Nervous System (CNS) diseases and disorders. It is developing a proprietary nasal spray formulation of diazepam, licensed from SK Biopharmaceuticals, to be used as rescue medication in patients with certain seizure disorders. The company was acquired by Acorda in 2012.

Key Metrics

Founded Year

2010

Location

Morrisville, United States

Stage

Acqui-Hired

Total Funding

$1.5M in 2 rounds

Latest Funding Round

Conventional Debt, May 06, 2011, $*****

Ranked

432^nd among 492 active competitors

Employee Count

5 as on May 31, 2026

Similar Companies

Dyne Therapeutics & 48 more

View Neuronex's full profile

Neuronex is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neuronex, Inc. CIN: 272315094 , United States, Active	Dec 31, 2009	-	-	-

Neuronex has raised a total funding of $1.5M over 2 rounds. Its first funding round was on Oct 07, 2010.

Here is the list of recent funding rounds of Neuronex:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 06, 2011	3546651	Conventional Debt	7007553	6110891	1690986	6277820
Oct 07, 2010	4454884	Series A	1109584	3853283	8125598	1085121

Access funding benchmarks and valuations. Sign up today!

View details of Neuronex's funding rounds and investors

Neuronex's employee count trend

Neuronex has 5 employees as of May 26. Here is Neuronex's employee count trend over the years:

Uncover Neuronex's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neuronex include Jazz Pharmaceuticals, Pacira and Intra-Cellular Therapies. Here is the list of Top 10 competitors of Neuronex, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	72/100
3rd	Intra-Cellular Therapies 2002, New York City (United States), Acquired	Developer of therapeutics for psychiatric and neurologic diseases	$80.9M	BB Biotech, International Biotechnology Trust ... & 6 others	70/100
4th	Lundbeck 1915, Copenhagen (Denmark), Public	Developer of drugs for treating CNS disorders	-	Impact Fund Denmark, Europa	69/100
5th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
6th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	Credit Suisse First Boston, HBM Healthcare Investments ... & 27 others	68/100
7th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Forbion & 10 others	68/100
8th	Neumora 2020, Watertown (United States), Public	Developer of precision medicines for neuropsychiatric disorders and neurodegenerative disorders	$612M	Arch Venture Partners, Mubadala & 18 others	67/100
9th	PureTech Health 2001, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual	67/100
10th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	BB Biotech, International Biotechnology Trust ... & 5 others	67/100
432nd	Neuronex 2010, Morrisville (United States), Acqui-Hired	Nasal spray formulation of diazepam to treat epilepsy.	$1.5M	-	24/100